Skip to main content
×
Home
    • Aa
    • Aa

Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents

  • Jonathan Bar (a1), Alexa David (a1), Tarek Khader (a1), Mary Mulcare (a1) (a2) and Christopher Tedeschi (a2) (a3)...
Abstract
Abstract Introduction

The use of direct oral anticoagulants (DOACs) such as rivaroxaban (Xarelto) is increasingly common. However, therapies for reversing anticoagulation in the event of hemorrhage are limited. This study investigates the ability of hemostatic agents to improve the coagulation of rivaroxaban-anticoagulated blood, as measured by rotational thromboelastometry (ROTEM).

Hypothesis/Problem

If a chitosan-based hemostatic agent (Celox), which works independently of the clotting cascade, is applied to rivaroxaban-anticoagulated blood, it should improve coagulation by decreasing clotting time (CT), decreasing clot formation time (CFT), and increasing maximum clot firmness (MCF). If a kaolin-based hemostatic agent (QuikClot Combat Gauze), which works primarily by augmenting the clotting cascade upstream of factor Xa (FXa), is applied to rivaroxaban-anticoagulated blood, it will not be effective at improving coagulation.

Methods

Patients (age >18 years; non-pregnant) on rivaroxaban, presenting to the emergency department (ED) at two large, university-based medical centers, were recruited. Subjects (n=8) had blood drawn and analyzed using ROTEM with and without the presence of a kaolin-based and a chitosan-based hemostatic agent. The percentage of patients whose ROTEM parameters responded to the hemostatic agent and percent changes in coagulation parameters were calculated.

Results

Data points analyzed included: CT, CFT, and MCF. Of the samples treated with a kaolin-based hemostatic agent, seven (87.5%) showed reductions in CT, eight (100.0%) showed reductions in CFT, and six (75.0%) showed increases in MCF. The average percent change in CT, CFT, and MCF for all patients was 32.5% (Standard Deviation [SD]: 286; Range:-75.3 to 740.7%); -66.0% (SD:14.4; Range: -91.4 to -44.1%); and 4.70% (SD: 6.10; Range: -4.8 to 15.1%), respectively. The corresponding median percent changes were -68.1%, -64.0%, and 5.2%. Of samples treated with a chitosan-based agent, six (75.0%) showed reductions in CT, three (37.5%) showed reductions in CFT, and five (62.5%) showed increases in MCF. The average percent changes for CT, CFT, and MCF for all patients were 165.0% (SD: 629; Range:-96.9 to 1718.5%); 139.0% (SD: 174; Range: -83.3 to 348.0%); and -8.38% (SD: 32.7; Range:-88.7 to 10.4%), respectively. The corresponding median percent changes were -53.7%, 141.8%, and 3.0%.

Conclusions

Rotational thromboelastometry detects changes in coagulation parameters caused by hemostatics applied to rivaroxaban-anticoagulated blood. These changes trended in the direction towards improved coagulability, suggesting that kaolin-based and chitosan-based hemostatics may be effective at improving coagulation in these patients.

Bar J , David A , Khader T , Mulcare M , Tedeschi C . Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents. Prehosp Disaster Med. 2017;32(5):580587.

Copyright
Corresponding author
Correspondence: Jonathan Bar, MD 619 S 16th St #2F Philadelphia, Pennsylvania 19146 USA E-mail: Jonathan.Bar@uphs.upenn.edu
Footnotes
Hide All

Conflict of interest/funding: Jonathan Bar, Alexa David, and Tarek Khader received Federal Work-Study funds for personal expenses incurred as part of this project. All authors have no conflicts of interest to declare.

Footnotes
References
Hide All
1. A Gómez-Outes , ML Suárez-Gea , R Lecumberri , AI Terleira-Fernández , E Vargas-Castrillón . Direct acting oral anticoagulants: pharmacology, indications, management, and future perspectives. Eur J Haematol. 2015;95:389-404.

2. NR Desai , AA Krumme , S Schneeweiss , et al. Patterns of initiation of oral anti-coagulants in patients with atrial fibrillation quality and cost implications. Am J Med. 2014;127(11):1075.e1-1082.e1.

3. SK Young , HA Al-Mondhiry , SJ Vaida , A Ambrose , JJ Botti . Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature. Pharmacotherapy. 2008;28(12):1531-1536.

4. RG Hart , LA Pearce , MI Aguilar . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.

5. SK Kakkos , GI Kirkilesis , IA Tsolakis . Editor’s Choice – efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014;48:565-575.

7. B Sorensen , DR Spahn , P Innerhofer , M Spannagl , R Rossaint . Clinical review: prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011;15:201.

8. M Makris , JJ Van Veen , CR Tait , AD Mumford , M Laffan . Guideline on the management of bleeding in patients on anti- thrombotic agents. Br J Haematol. 2013;160:35-46.

10. D Kubitza , S Haas . Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006;15:843-855.

11. SD Gordy , P Rhee , MA Schreiber . Military applications of novel hemostatic devices. Expert Rev Med Devices. 2011;8(1):41-47.

12. ED Cox , MA Schreiber , J McManus , CE Wade , JB Holcomb . New hemostatic agents in the combat setting. Transfusion. 2009;49(Suppl):248S-255S.

13. J Granville-Chapman , N Jacobs , M Midwinter . Prehospital hemostatic dressings: a systematic review. Injury. 2011;42(5):447-459.

14. P Rhee , C Brown , M Martin , et al. QuikClot use in trauma for hemorrhage control: case series of 103 documented uses. J Trauma. 2008;64:1093-1099.

15. PN Walsh . The effects of Collagen and Kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Br J Haematol. 1972;22:393-405.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Prehospital and Disaster Medicine
  • ISSN: 1049-023X
  • EISSN: 1945-1938
  • URL: /core/journals/prehospital-and-disaster-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 3
Total number of PDF views: 39 *
Loading metrics...

Abstract views

Total abstract views: 449 *
Loading metrics...

* Views captured on Cambridge Core between 19th June 2017 - 18th October 2017. This data will be updated every 24 hours.